Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−5.54 USD
−43.55 M USD
2.83 M USD
20.08 M
About Dianthus Therapeutics, Inc.
Sector
Industry
CEO
Marino Garcia
Website
Headquarters
New York
Founded
2015
FIGI
BBG00FB2NPZ0
Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company. It designs and delivers novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company was founded on June 17, 2015 and is headquartered in New York, NY.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of DNTH is 29.00 USD — it has increased by 1.67% in the past 24 hours. Watch Dianthus Therapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Dianthus Therapeutics, Inc. stocks are traded under the ticker DNTH.
DNTH stock has risen by 7.44% compared to the previous week, the month change is a 13.34% rise, over the last year Dianthus Therapeutics, Inc. has showed a 153.94% increase.
We've gathered analysts' opinions on Dianthus Therapeutics, Inc. future price: according to them, DNTH price has a max estimate of 84.00 USD and a min estimate of 36.00 USD. Watch DNTH chart and read a more detailed Dianthus Therapeutics, Inc. stock forecast: see what analysts think of Dianthus Therapeutics, Inc. and suggest that you do with its stocks.
DNTH reached its all-time high on Mar 26, 2019 with the price of 336.00 USD, and its all-time low was 5.14 USD and was reached on Dec 21, 2022. View more price dynamics on DNTH chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
DNTH stock is 13.11% volatile and has beta coefficient of 1.29. Track Dianthus Therapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is Dianthus Therapeutics, Inc. there?
Today Dianthus Therapeutics, Inc. has the market capitalization of 878.05 M, it has increased by 0.07% over the last week.
Yes, you can track Dianthus Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Dianthus Therapeutics, Inc. is going to release the next earnings report on Mar 20, 2025. Keep track of upcoming events with our Earnings Calendar.
DNTH earnings for the last quarter are −0.74 USD per share, whereas the estimation was −0.59 USD resulting in a −24.45% surprise. The estimated earnings for the next quarter are −0.70 USD per share. See more details about Dianthus Therapeutics, Inc. earnings.
Dianthus Therapeutics, Inc. revenue for the last quarter amounts to 2.17 M USD, despite the estimated figure of 741.14 K USD. In the next quarter, revenue is expected to reach 928.14 K USD.
DNTH net income for the last quarter is −25.17 M USD, while the quarter before that showed −17.61 M USD of net income which accounts for −42.98% change. Track more Dianthus Therapeutics, Inc. financial stats to get the full picture.
No, DNTH doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 8, 2024, the company has 53.00 employees. See our rating of the largest employees — is Dianthus Therapeutics, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Dianthus Therapeutics, Inc. EBITDA is −82.47 M USD, and current EBITDA margin is −1.69 K%. See more stats in Dianthus Therapeutics, Inc. financial statements.
Like other stocks, DNTH shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Dianthus Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Dianthus Therapeutics, Inc. technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Dianthus Therapeutics, Inc. stock shows the neutral signal. See more of Dianthus Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.